


# DEPOVAX™ PLATFORM: MAKING VACCINES BETTER




## DEPOVAX™ VACCINE PLATFORM


DepoVax™ technology provides unique single-dose capability. It is a novel three-step process that uses liposomes to encapsulate targeted antigens and an adjuvant. The vaccine formulation relies on a hydrophobic oil carrier to complete the depot effect.



**BEGIN WITH ANY ANTIGEN AND ADJUVANT**  
proteins, peptides, DNA, RNA, etc.



**ENCLOSE IN LIPOSOME**  
encapsulates antigens and adjuvants



**COMPLETE DEPOVAX™ PLATFORM**  
liposomes in cGMP oil

## DEPOVAX™ VACCINE ENHANCEMENT PLATFORM

### THE DEPOT EFFECT

The DepoVax™ platform holds the antigens in place, causing a “depot effect” that presents antigen and adjuvant to the immune system in a unique way, resulting in a stronger, faster and longer lasting immune response. DepoVax™ technology enhances both infectious disease and therapeutic cancer vaccines.

### CELLULAR & HUMORAL EFFICACY

- Short timeframe to efficacy, reducing the number of doses to as little as one for a range of vaccines including influenza, Hepatitis B and whooping cough
- 100% tumor elimination in three independent pre-clinical models of cancer following a single vaccination

## SIGNIFICANCE OF DEPOVAX™ PLATFORM

Enhances delivery and in-vivo efficacy of antigen

Strong and long lasting humoral and cellular immune responses

Highly promising for development of prophylactic and therapeutic vaccines

Dry storage formulation for enhanced stability of antigens and adjuvants


Ease of formulation and administration in the clinic; re-suspends in 30 seconds

Backed by strong patent portfolio with broad applicability in the US, EU, AU, Asia and Canada

Proven scaled manufacturing process and good safety profile

Currently in Phase 1 clinical studies in the US

## DEPOVAX™ BASED PANDEMIC INFLUENZA VACCINE



Dramatically higher titers with one dose of DepoVax™ compared with two doses of an alum-adsorbed control vaccine.

## PARTNERS MAKING VACCINES BETTER WITH DEPOVAX™ PLATFORM

Defence Research & Development Canada:  
anti-anthrax vaccines

FIT Biotech:  
therapeutic HIV vaccine

Dana Farber Cancer Institute:  
advance therapeutic vaccines

Partnership opportunities are available to use Immunovaccine's patented DepoVax™ vaccine delivery technology

La Jolla Institute for Allergy & Immunology:  
infectious disease vaccines

National Institutes of Health:  
HIV and malaria vaccines

Scancell Ltd:  
advance cancer vaccines

Pirouz M. Daftarian, Marc Mansour, Anita C. Benoit, Bill Pohajdak, David W. Hoskin, Robert G. Brown, W. Martin Kast, Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome encapsulated CTL-T helper fusion peptide in a water in oil emulsion, Vaccine 24 (2006), 5235-5244  
Pirouz M Daftarian, Marc Mansour, Bill Pohajdak, Antar Fuentes-Ortega, Ella Korets-Smith, Lisa MacDonald, Genevieve Weir, Robert G. Brown and W. Martin Kast, Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides, Translational Medicine, June 7, 2007